CRSP
Crispr Therapeutics AG
55.80$
-5.5%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 24,059.9% | -1,071.1% | -171.0% | -3,080.6% | 19.6% | -33,152.4% | 59.0% | -113,702.1% | -70.4% | -407.9% | -9,829.5% | |
| – | 51.4% | 17.9% | 7.4% | 112.6% | 1.6% | 1,277.3% | 2.0% | 5,544.0% | 5.4% | 55.0% | 555.0% | |
| – | 1,491.5% | 210.0% | 46.0% | 1,119.9% | 15.2% | 9,181.9% | 11.2% | 22,464.9% | 21.9% | 247.3% | 2,065.5% | |
| – | 1,391.1% | -674.7% | 50.3% | 1,114.5% | 17.1% | 9,440.2% | 11.2% | 25,325.0% | – | – | – | |
| – | 32,942.5% | 34.5% | -61.9% | 337.7% | -16.7% | 4,650.9% | 2.9% | 4,551.6% | -52.3% | 446.5% | 2,047.9% | |
| – | 467.2% | 58.4% | 19.1% | 88.8% | 2.3% | 2,553.3% | 8.9% | 8,529.4% | 2.6% | 5.4% | 26.0% | |
| – | -467.2% | 617.4% | -20.3% | -88.8% | 0.5% | -75,267.0% | -113.4% | -59,324.5% | 101.3% | -801.4% | -906.1% | |
| – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | 23,831.6% | 2,227.3% | 6.4% | -1.8% | 148.8% | 141,328.5% | 27.5% | 8,851.4% | – | – | 2,030.0% | |
| – | 15,481.4% | 678.0% | – | – | – | – | – | – | – | – | – | |
| – | 39,163.2% | 3,548.0% | 6.4% | 10,113.1% | 148.8% | 141,328.5% | 27.5% | 8,851.4% | 16.9% | 948.5% | 12,137.5% | |
| – | 62,759.5% | 3,089.8% | -184.8% | 6,943.0% | 168.9% | 32,914.6% | -26.9% | -164,193.6% | 48.0% | -260.8% | 1,404.6% | |
| – | 23,592.7% | -1,129.5% | -190.0% | -3,169.4% | 17.3% | -35,705.7% | 50.1% | -122,231.4% | -72.9% | -413.4% | -9,855.5% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.